We are live on ! Find out more

2,717 hedge funds and large institutions have $119B invested in Amgen in 2023 Q4 according to their latest regulatory filings, with 343 funds opening new positions, 979 increasing their positions, 1,048 reducing their positions, and 89 closing their positions.

New
Increased
Maintained
Reduced
Closed

285% more first-time investments, than exits

New positions opened: 343 | Existing positions closed: 89

9% more capital invested

Capital invested by funds: $109B → $119B (+$9.42B)

9% more funds holding

Funds holding: 2,5022,717 (+215)

1.02% more ownership

Funds ownership: 75.94%76.96% (+1%)

6% less call options, than puts

Call options by funds: $1.91B | Put options by funds: $2.03B

7% less repeat investments, than reductions

Existing positions increased: 979 | Existing positions reduced: 1,048

9% less funds holding in top 10

Funds holding in top 10: 8779 (-8)

Holders
2,717
Holders Change
+215
Holders Change %
+8.59%
% of All Funds
39.55%
Holding in Top 10
79
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-9.2%
% of All Funds
1.15%
New
343
Increased
979
Reduced
1,048
Closed
89
Calls
$1.91B
Puts
$2.03B
Net Calls
-$117M
Net Calls Change
-$84.7M

AMGN Hedge Fund Activity: Q4 2023 in Review

2,717 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Amgen (AMGN) for Q4 2023, worth a combined $119B — up 8.6% from $109B a quarter earlier.

Buyers outnumbered sellers: 343 funds opened new AMGN positions and 89 closed out — a net gain of 254 holders — while 979 added to existing stakes and 1,048 trimmed.

The largest buyer was Barclays, adding an estimated $378M. The largest seller was Capital Research Global Investors, cutting an estimated $487M.

  • 2,717 institutional investors held Amgen (AMGN) as of Q4 2023, up from 2,502 in Q3 2023.
  • Funds reported $119B of Amgen stock for Q4 2023, up 8.6% quarter-over-quarter.
  • 343 funds opened new Amgen positions in Q4 2023 and 89 closed out, a net change of +254 holders.
  • The largest Amgen buyer in Q4 2023 was Barclays, an estimated $378M added.
  • The largest Amgen seller in Q4 2023 was Capital Research Global Investors, an estimated $487M sold.

Based on aggregated 13F filings for Q4 2023.